300
Participants
Start Date
January 20, 2017
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2029
Anti-TNF
Subject receives anti-TNF antibodies open-label as per guidelines
Anti-IL12/23
Subject receives anti-IL12/23 antibodies open-label as per guidelines
Anti-IL17
Subject receives anti-IL17 antibodies open-label as per guidelines
Dupilumab
Subject receives Dupilumab open-label as per guidelines
Anti-IL23
Subject receives anti-IL23 antibodies open-label as per guidelines
Baricitinib
Subject receives Baricitinib open-label as per guidelines
Abrocitinib
Subject receives Abrocitinib open-label as per guidelines
Upadacitinib
Subject receives Upadacitinib open-label as per guidelines
Tralokinumab
Subject receives Tralokinumab open-label as per guidelines
Lebrikizumab
Subject receives Lebrikizumab open-label as per guidelines
Nemolizumab
Subject receives Nemolizumab open-label as per guidelines
RECRUITING
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel
Prof. Dr. Stephan Weidinger
OTHER